Cumberland Pharmaceuticals (CPIX) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research downgraded shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) from a buy rating to a hold rating in a research note issued to investors on Monday morning.

According to Zacks, “Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company’s lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients. “

Separately, B. Riley dropped their price target on Cumberland Pharmaceuticals from $9.25 to $8.75 and set a buy rating on the stock in a research note on Friday, August 17th.

NASDAQ CPIX traded down $0.31 during trading on Monday, reaching $5.30. The company’s stock had a trading volume of 1,400 shares, compared to its average volume of 18,881. The stock has a market capitalization of $82.67 million, a PE ratio of -75.70 and a beta of 0.48. Cumberland Pharmaceuticals has a 1-year low of $5.06 and a 1-year high of $7.96. The company has a quick ratio of 3.53, a current ratio of 3.96 and a debt-to-equity ratio of 0.20.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.09. The firm had revenue of $10.16 million for the quarter, compared to the consensus estimate of $9.94 million. Cumberland Pharmaceuticals had a negative return on equity of 3.12% and a negative net margin of 11.16%. As a group, equities analysts anticipate that Cumberland Pharmaceuticals will post -0.4 EPS for the current year.

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 6.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 377,209 shares of the specialty pharmaceutical company’s stock after purchasing an additional 23,709 shares during the period. Renaissance Technologies LLC owned about 2.40% of Cumberland Pharmaceuticals worth $2,312,000 at the end of the most recent quarter. 34.49% of the stock is owned by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects.

Recommended Story: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply